RBM23

Across TCGA pan-cancer cohorts, RBM23 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM23 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM23 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM23 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where RBM23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.511	0.833	.011	19	view →
PDAC	OS	Tertile	III,IV	0.842	0.183	.024	18	view →
CCRCC	DFS	Quartile	All	0.912	0.446	.006	13	view →
LSCC	OS	Median	II,III,IV	0.887	0.649	.003	10	view →
LUAD	DFS	Quartile	All	0.757	0.520	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM23–HNSC (DFS)

Open the HNSC breakdown →